FDA cleared the BioFlo Hybrid PICC with ENDEXO Technology and PASV Valve Technology; BioFlo PICC with ENDEXO Technology and PASV Valve Technology; BioFlo PICC with ENDEXO Technology; BioFlo Midline Catheter; Xcela Power Injectable PICC; Xcela PICC with PASV Valve Technology; Xcela Hybrid PICC with PASV Valve Technology from Spectrum Vascular on Dec 16, 2025 under K252373, a traditional 510(k). The device falls under product code LJS, Catheter, Intravascular, Therapeutic, Long-Term Greater Than 30 Days, regulated at 21 CFR 880.5970 as a Class 2 device. The review panel was General Hospital.

FDA logged the submission as received on Jul 30, 2025. The decision came 139 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Spectrum Vascular has 3 other decisions in the tracker over the last 12 months: K260165 (Unimpregnated Central Venous Catheter), K261455 (Arterial Pressure Monitoring Set/Tray), K254278 (Arterial Pressure Monitoring Set/Tray).